Loading…

The gold standard program (GSP) for smoking cessation: a cohort study of its effectiveness among smokers with and without cancer

Smoking cessation treatment is an important prognostic factor for survival after a cancer diagnosis, especially for tobacco-related cancers. After being diagnosed with lung cancer, approximately 50% of patients continue smoking or frequently relapse after a quit attempt. Given the importance of smok...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-8
Main Authors: Lauridsen, S. V., Jensen, B. T., Tønnesen, H., Dalton, S. O., Rasmussen, M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c435t-dfdce60debbe21e7bac5883ae95a9574d28070f218d4be537fabeb574498a0d83
cites cdi_FETCH-LOGICAL-c435t-dfdce60debbe21e7bac5883ae95a9574d28070f218d4be537fabeb574498a0d83
container_end_page 8
container_issue ahead-of-print
container_start_page 1
container_title Acta oncologica
container_volume ahead-of-print
creator Lauridsen, S. V.
Jensen, B. T.
Tønnesen, H.
Dalton, S. O.
Rasmussen, M.
description Smoking cessation treatment is an important prognostic factor for survival after a cancer diagnosis, especially for tobacco-related cancers. After being diagnosed with lung cancer, approximately 50% of patients continue smoking or frequently relapse after a quit attempt. Given the importance of smoking cessation treatment for cancer survivors, the objective was to compare the effectiveness of a 6-week intensive smoking cessation intervention, the Gold Standard Program (GSP), among cancer survivors compared with smokers without cancer. Second, we compared successful quitting among socioeconomically disadvantaged cancer survivors with that among nondisadvantaged cancer survivors. This was a cohort study based on 38,345 smokers from the Danish Smoking Cessation Database (2006-2016). Linkage to the National Patient Register was used to identify cancer survivors undergoing the GSP after being diagnosed with cancer (except nonmelanoma skin cancer). Linkage to the Danish Civil Registration System was used to identify participants who died, went missing, or emigrated before the follow-up. Logistic regression models were applied to evaluate effectiveness. Six percent (2438) of the included smokers were cancer survivors at the time they undertook the GSP. Their 6-month successful quitting showed no difference compared to that of smokers without cancer, neither before nor after adjustment; 35% versus 37% in crude rates and an aOR of 1.13 (95% CI: 0.97-1.32). Likewise, the results for disadvantaged compared to nondisadvantaged cancer survivors were not significantly different (32% versus 33% and an adjusted aOR of 0.87 (95% CI 0.69-1.11)). Overall, an intensive smoking cessation program seems effective in helping both people without cancer and cancer survivors become successful quitters.
doi_str_mv 10.1080/0284186X.2023.2228445
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_0284186X_2023_2228445</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2834000577</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-dfdce60debbe21e7bac5883ae95a9574d28070f218d4be537fabeb574498a0d83</originalsourceid><addsrcrecordid>eNp9kV-PEyEUxSdG49bVj6DhcX2YCgwUxifNRleTJpq4JvtG-HNp0ZmhAmPTNz-61Hb30YcbIPzOOck9TfOS4CXBEr_BVDIiV3dLimm3pLQ-GX_ULMiKk5bS1d3jZnFk2iN00TzL-QfGFRX8aXPRCYZ534lF8-d2C2gTB4dy0ZPTyaFdipukR3R18-3ra-RjQnmMP8O0QRZy1iXE6S3SyMZtTKXKZndA0aNQMgLvwZbwG6ZKIj3GKjqKIWW0D2WLasS_S5wLsnqykJ43T7weMrw4n5fN948fbq8_tesvN5-v369byzpeWuedhRV2YAxQAsJoy6XsNPRc91wwRyUW2FMiHTPAO-G1AVM_WC81drK7bNYn37yH3WzULoVRp4OKOqhh3tUxdVQGRZyxzPFeCUeYYthIpXtqFOXgjcNgsGTV7upkV7f1a4Zc1BiyhWHQE8Q5Kyo7VvfNhagoP6E2xZwT-IdsgtWxS3XfpTp2qc5dVt2rc8RsRnAPqvvyKvDuBISptjTqfUyDU0Ufhph8qtsNWXX_z_gLtn6wxg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2834000577</pqid></control><display><type>article</type><title>The gold standard program (GSP) for smoking cessation: a cohort study of its effectiveness among smokers with and without cancer</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Lauridsen, S. V. ; Jensen, B. T. ; Tønnesen, H. ; Dalton, S. O. ; Rasmussen, M.</creator><creatorcontrib>Lauridsen, S. V. ; Jensen, B. T. ; Tønnesen, H. ; Dalton, S. O. ; Rasmussen, M.</creatorcontrib><description>Smoking cessation treatment is an important prognostic factor for survival after a cancer diagnosis, especially for tobacco-related cancers. After being diagnosed with lung cancer, approximately 50% of patients continue smoking or frequently relapse after a quit attempt. Given the importance of smoking cessation treatment for cancer survivors, the objective was to compare the effectiveness of a 6-week intensive smoking cessation intervention, the Gold Standard Program (GSP), among cancer survivors compared with smokers without cancer. Second, we compared successful quitting among socioeconomically disadvantaged cancer survivors with that among nondisadvantaged cancer survivors. This was a cohort study based on 38,345 smokers from the Danish Smoking Cessation Database (2006-2016). Linkage to the National Patient Register was used to identify cancer survivors undergoing the GSP after being diagnosed with cancer (except nonmelanoma skin cancer). Linkage to the Danish Civil Registration System was used to identify participants who died, went missing, or emigrated before the follow-up. Logistic regression models were applied to evaluate effectiveness. Six percent (2438) of the included smokers were cancer survivors at the time they undertook the GSP. Their 6-month successful quitting showed no difference compared to that of smokers without cancer, neither before nor after adjustment; 35% versus 37% in crude rates and an aOR of 1.13 (95% CI: 0.97-1.32). Likewise, the results for disadvantaged compared to nondisadvantaged cancer survivors were not significantly different (32% versus 33% and an adjusted aOR of 0.87 (95% CI 0.69-1.11)). Overall, an intensive smoking cessation program seems effective in helping both people without cancer and cancer survivors become successful quitters.</description><identifier>ISSN: 0284-186X</identifier><identifier>ISSN: 1651-226X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.1080/0284186X.2023.2228445</identifier><identifier>PMID: 37405937</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>cancer ; Cancer and Oncology ; Cancer och onkologi ; Clinical Medicine ; disadvantaged smokers ; Intensive smoking cessation intervention ; Klinisk medicin ; Medical and Health Sciences ; Medicin och hälsovetenskap</subject><ispartof>Acta oncologica, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-8</ispartof><rights>2023 Acta Oncologica Foundation 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-dfdce60debbe21e7bac5883ae95a9574d28070f218d4be537fabeb574498a0d83</citedby><cites>FETCH-LOGICAL-c435t-dfdce60debbe21e7bac5883ae95a9574d28070f218d4be537fabeb574498a0d83</cites><orcidid>0000-0002-5485-2730 ; 0000-0003-2847-1544 ; 0000-0003-3174-9121 ; 0000-0001-6045-4723 ; 0000-0002-7161-3416</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37405937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/1dbc4d59-7d14-40b8-a92b-25efbd0eb084$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Lauridsen, S. V.</creatorcontrib><creatorcontrib>Jensen, B. T.</creatorcontrib><creatorcontrib>Tønnesen, H.</creatorcontrib><creatorcontrib>Dalton, S. O.</creatorcontrib><creatorcontrib>Rasmussen, M.</creatorcontrib><title>The gold standard program (GSP) for smoking cessation: a cohort study of its effectiveness among smokers with and without cancer</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>Smoking cessation treatment is an important prognostic factor for survival after a cancer diagnosis, especially for tobacco-related cancers. After being diagnosed with lung cancer, approximately 50% of patients continue smoking or frequently relapse after a quit attempt. Given the importance of smoking cessation treatment for cancer survivors, the objective was to compare the effectiveness of a 6-week intensive smoking cessation intervention, the Gold Standard Program (GSP), among cancer survivors compared with smokers without cancer. Second, we compared successful quitting among socioeconomically disadvantaged cancer survivors with that among nondisadvantaged cancer survivors. This was a cohort study based on 38,345 smokers from the Danish Smoking Cessation Database (2006-2016). Linkage to the National Patient Register was used to identify cancer survivors undergoing the GSP after being diagnosed with cancer (except nonmelanoma skin cancer). Linkage to the Danish Civil Registration System was used to identify participants who died, went missing, or emigrated before the follow-up. Logistic regression models were applied to evaluate effectiveness. Six percent (2438) of the included smokers were cancer survivors at the time they undertook the GSP. Their 6-month successful quitting showed no difference compared to that of smokers without cancer, neither before nor after adjustment; 35% versus 37% in crude rates and an aOR of 1.13 (95% CI: 0.97-1.32). Likewise, the results for disadvantaged compared to nondisadvantaged cancer survivors were not significantly different (32% versus 33% and an adjusted aOR of 0.87 (95% CI 0.69-1.11)). Overall, an intensive smoking cessation program seems effective in helping both people without cancer and cancer survivors become successful quitters.</description><subject>cancer</subject><subject>Cancer and Oncology</subject><subject>Cancer och onkologi</subject><subject>Clinical Medicine</subject><subject>disadvantaged smokers</subject><subject>Intensive smoking cessation intervention</subject><subject>Klinisk medicin</subject><subject>Medical and Health Sciences</subject><subject>Medicin och hälsovetenskap</subject><issn>0284-186X</issn><issn>1651-226X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kV-PEyEUxSdG49bVj6DhcX2YCgwUxifNRleTJpq4JvtG-HNp0ZmhAmPTNz-61Hb30YcbIPzOOck9TfOS4CXBEr_BVDIiV3dLimm3pLQ-GX_ULMiKk5bS1d3jZnFk2iN00TzL-QfGFRX8aXPRCYZ534lF8-d2C2gTB4dy0ZPTyaFdipukR3R18-3ra-RjQnmMP8O0QRZy1iXE6S3SyMZtTKXKZndA0aNQMgLvwZbwG6ZKIj3GKjqKIWW0D2WLasS_S5wLsnqykJ43T7weMrw4n5fN948fbq8_tesvN5-v369byzpeWuedhRV2YAxQAsJoy6XsNPRc91wwRyUW2FMiHTPAO-G1AVM_WC81drK7bNYn37yH3WzULoVRp4OKOqhh3tUxdVQGRZyxzPFeCUeYYthIpXtqFOXgjcNgsGTV7upkV7f1a4Zc1BiyhWHQE8Q5Kyo7VvfNhagoP6E2xZwT-IdsgtWxS3XfpTp2qc5dVt2rc8RsRnAPqvvyKvDuBISptjTqfUyDU0Ufhph8qtsNWXX_z_gLtn6wxg</recordid><startdate>20230705</startdate><enddate>20230705</enddate><creator>Lauridsen, S. V.</creator><creator>Jensen, B. T.</creator><creator>Tønnesen, H.</creator><creator>Dalton, S. O.</creator><creator>Rasmussen, M.</creator><general>Taylor &amp; Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D95</scope><orcidid>https://orcid.org/0000-0002-5485-2730</orcidid><orcidid>https://orcid.org/0000-0003-2847-1544</orcidid><orcidid>https://orcid.org/0000-0003-3174-9121</orcidid><orcidid>https://orcid.org/0000-0001-6045-4723</orcidid><orcidid>https://orcid.org/0000-0002-7161-3416</orcidid></search><sort><creationdate>20230705</creationdate><title>The gold standard program (GSP) for smoking cessation: a cohort study of its effectiveness among smokers with and without cancer</title><author>Lauridsen, S. V. ; Jensen, B. T. ; Tønnesen, H. ; Dalton, S. O. ; Rasmussen, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-dfdce60debbe21e7bac5883ae95a9574d28070f218d4be537fabeb574498a0d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>cancer</topic><topic>Cancer and Oncology</topic><topic>Cancer och onkologi</topic><topic>Clinical Medicine</topic><topic>disadvantaged smokers</topic><topic>Intensive smoking cessation intervention</topic><topic>Klinisk medicin</topic><topic>Medical and Health Sciences</topic><topic>Medicin och hälsovetenskap</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lauridsen, S. V.</creatorcontrib><creatorcontrib>Jensen, B. T.</creatorcontrib><creatorcontrib>Tønnesen, H.</creatorcontrib><creatorcontrib>Dalton, S. O.</creatorcontrib><creatorcontrib>Rasmussen, M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Lunds universitet</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lauridsen, S. V.</au><au>Jensen, B. T.</au><au>Tønnesen, H.</au><au>Dalton, S. O.</au><au>Rasmussen, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The gold standard program (GSP) for smoking cessation: a cohort study of its effectiveness among smokers with and without cancer</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>2023-07-05</date><risdate>2023</risdate><volume>ahead-of-print</volume><issue>ahead-of-print</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>0284-186X</issn><issn>1651-226X</issn><eissn>1651-226X</eissn><abstract>Smoking cessation treatment is an important prognostic factor for survival after a cancer diagnosis, especially for tobacco-related cancers. After being diagnosed with lung cancer, approximately 50% of patients continue smoking or frequently relapse after a quit attempt. Given the importance of smoking cessation treatment for cancer survivors, the objective was to compare the effectiveness of a 6-week intensive smoking cessation intervention, the Gold Standard Program (GSP), among cancer survivors compared with smokers without cancer. Second, we compared successful quitting among socioeconomically disadvantaged cancer survivors with that among nondisadvantaged cancer survivors. This was a cohort study based on 38,345 smokers from the Danish Smoking Cessation Database (2006-2016). Linkage to the National Patient Register was used to identify cancer survivors undergoing the GSP after being diagnosed with cancer (except nonmelanoma skin cancer). Linkage to the Danish Civil Registration System was used to identify participants who died, went missing, or emigrated before the follow-up. Logistic regression models were applied to evaluate effectiveness. Six percent (2438) of the included smokers were cancer survivors at the time they undertook the GSP. Their 6-month successful quitting showed no difference compared to that of smokers without cancer, neither before nor after adjustment; 35% versus 37% in crude rates and an aOR of 1.13 (95% CI: 0.97-1.32). Likewise, the results for disadvantaged compared to nondisadvantaged cancer survivors were not significantly different (32% versus 33% and an adjusted aOR of 0.87 (95% CI 0.69-1.11)). Overall, an intensive smoking cessation program seems effective in helping both people without cancer and cancer survivors become successful quitters.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>37405937</pmid><doi>10.1080/0284186X.2023.2228445</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-5485-2730</orcidid><orcidid>https://orcid.org/0000-0003-2847-1544</orcidid><orcidid>https://orcid.org/0000-0003-3174-9121</orcidid><orcidid>https://orcid.org/0000-0001-6045-4723</orcidid><orcidid>https://orcid.org/0000-0002-7161-3416</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0284-186X
ispartof Acta oncologica, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-8
issn 0284-186X
1651-226X
1651-226X
language eng
recordid cdi_crossref_primary_10_1080_0284186X_2023_2228445
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects cancer
Cancer and Oncology
Cancer och onkologi
Clinical Medicine
disadvantaged smokers
Intensive smoking cessation intervention
Klinisk medicin
Medical and Health Sciences
Medicin och hälsovetenskap
title The gold standard program (GSP) for smoking cessation: a cohort study of its effectiveness among smokers with and without cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A35%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20gold%20standard%20program%20(GSP)%20for%20smoking%20cessation:%20a%20cohort%20study%20of%20its%20effectiveness%20among%20smokers%20with%20and%20without%20cancer&rft.jtitle=Acta%20oncologica&rft.au=Lauridsen,%20S.%20V.&rft.date=2023-07-05&rft.volume=ahead-of-print&rft.issue=ahead-of-print&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=0284-186X&rft.eissn=1651-226X&rft_id=info:doi/10.1080/0284186X.2023.2228445&rft_dat=%3Cproquest_cross%3E2834000577%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c435t-dfdce60debbe21e7bac5883ae95a9574d28070f218d4be537fabeb574498a0d83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2834000577&rft_id=info:pmid/37405937&rfr_iscdi=true